weight loss – Medxy AI

Aggressive Risk Factor Management Improves 12‑Month Ablation Success: Insights from the ARREST‑AF Randomized Trial

By MedXY 12/02/2025

In patients with overweight/obesity and cardiometabolic comorbidity undergoing first-time AF ablation, a structured, physician‑led program of lifestyle and risk‑factor modification (LRFM) improved freedom from atrial arrhythmia at 12 months versus usual care (61% vs 40%).

Diabetes & Endocrinology news

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

By MedXY 11/14/2025

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promising but require randomized, biomarker‑driven studies to define metabolic and reproductive benefits and safety in this population.

Diabetes & Endocrinology Internal Medicine news

Weekly Amylin Agonist Eloralintide Produces 10–21% Weight Loss at 48 Weeks in Phase 2 Trial

By MedXY 11/06/2025

In a 48‑week multicenter phase 2 trial, weekly amylin receptor agonist eloralintide produced dose‑dependent mean weight loss of 9.4%–20.9% versus 0.4% for placebo, with improved waist circumference and cardiometabolic markers; tolerability improved with stepwise dose escalation.

Diabetes & Endocrinology news Urology

Obesity Interventions and Male Fertility: Unraveling the Effects of Weight Loss on Reproductive Health

By MedXY 10/12/2025

This systematic review and meta-analysis evaluates the effects of obesity interventions—lifestyle modification, pharmacotherapy, and bariatric surgery—on male fertility, highlighting improvements with lifestyle changes and limited benefits from surgical weight loss.

Clinical Updates Diabetes & Endocrinology Internal Medicine news Specialties

Tirzepatide Influences Muscle Composition Favorably Amid Weight Loss in Type 2 Diabetes: Insights from SURPASS-3 MRI Substudy

By MedXY 09/19/2025

In type 2 diabetes patients, tirzepatide treatment led to significant reductions in muscle fat infiltration and adaptive decreases in muscle volume over 52 weeks, suggesting beneficial effects on muscle health concurrent with weight loss.

Family Medicine & Nutrition news

From Plate to Progress: Five Scientifically Proven Diets to Help Manage Obesity Effectively

By MedXY 09/18/2025

Explore five scientifically supported dietary patterns that aid effective weight loss for individuals struggling with obesity, emphasizing balanced nutrition and sustainable lifestyle changes.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

By MedXY 09/17/2025

Combining aerobic and resistance exercise with diet-induced weight loss in obese older adults significantly improves insulin secretion, preserves CNTFRα levels, and increases IGF-1, enhancing metabolic and physical function.

Diabetes & Endocrinology news

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial

By MedXY 09/08/2025

The OASIS 2 trial shows oral semaglutide 50 mg significantly reduces body weight in East Asian adults with overweight or obesity, with or without type 2 diabetes, offering a promising therapeutic option with manageable safety profile.

Diabetes & Endocrinology Specialties

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

By MedXY 09/07/2025

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.

Clinical Updates Diabetes & Endocrinology news

Advancing Obesity Management: Once-Monthly Maridebart Cafraglutide Demonstrates Significant Weight Loss Efficacy

By MedXY 09/07/2025

Maridebart cafraglutide, a novel once-monthly peptide-antibody conjugate, significantly reduces body weight in individuals with obesity, with and without type 2 diabetes, offering a new therapeutic option based on phase 2 trial results.

Diabetes & Endocrinology Specialties

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

By MedXY 08/28/2025

A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option for obesity management.

Cardiology Family Medicine & Nutrition Specialties

Morning or Evening? The Science Behind The Best Time to Exercise for Weight Loss and Muscle Growth

By MedXY 08/22/2025

Discover how exercising at 7 AM or 7 PM can boost weight loss and muscle growth, tailored to your body's rhythms and lifestyle.

news OB/GYN & Women's Health Specialties

Weight Reduction Before Conception: Enhancing Fertility and Reducing Pregnancy Complications in Overweight and Obese Women

By MedXY 08/19/2025

A 10%-25% preconception weight loss in overweight or obese women modestly increases pregnancy likelihood and significantly lowers gestational diabetes and hypertensive complication risks, improving maternal and neonatal outcomes.

Diabetes & Endocrinology Internal Medicine news Specialties

Microbiota-Mediated Weight Loss: Insights from the WLM3P Multicomponent Program in Obesity

By MedXY 08/18/2025

The WLM3P weight loss program significantly remodels gut microbiota, enriching beneficial bacteria such as Faecalibacterium, which associates with improved fat and visceral fat loss in adults with obesity compared to standard low-carb diets.

Family Medicine & Nutrition Internal Medicine news Specialties

Comparative Impact of 4:3 Intermittent Fasting Versus Daily Caloric Restriction on Eating Behaviors and Appetite Hormones Over 12 Months

By MedXY 08/18/2025

A 12-month trial reveals 4:3 intermittent fasting improves binge and uncontrolled eating behaviors more than daily caloric restriction, correlating with greater weight loss, while appetite hormone changes do not differ significantly between methods.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Top 10 Weight Loss Pitfalls and How to Avoid Them: A Science-Based Guide

By MedXY 08/17/2025

Uncover the ten most common weight loss misconceptions and pitfalls, and learn scientifically grounded practices to achieve sustainable, healthy fat loss.

Family Medicine & Nutrition news Specialties

5 Hidden Weight Gain Traps Sabotaging Your Diet — And How to Avoid Them

By MedXY 08/17/2025

Discover five common pitfalls that secretly lead to weight gain during dieting, and learn science-backed strategies for healthy, sustainable weight loss.

Diabetes & Endocrinology news Specialties

Debunking Weight Loss Myths: Avoid These Pitfalls for More Effective and Healthy Weight Loss

By MedXY 08/17/2025

This article explores common weight loss misconceptions, offering scientific insights and strategies for safe and sustainable fat loss.

Cardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

By MedXY 08/17/2025

Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.

Cardiology Diabetes & Endocrinology news Specialties

Effect of a Ketogenic Diet, Time-Restricted Eating, or Alternate-Day Fasting on Weight Loss in Adults with Obesity: A Randomized Clinical Trial

By MedXY 08/08/2025

This clinical trial compares the weight loss effects of ketogenic diet, time-restricted eating, and alternate-day fasting against a Mediterranean diet in adults with obesity over three months.